Hi there,

If you think Democracy Now!’s reporting is a critical line of defense against war, climate catastrophe and authoritarianism, please make your donation of $10 or more right now. Today, a generous donor will TRIPLE your donation, which means it’ll go 3x as far to support our independent journalism. Democracy Now! is funded by you, and that’s why we’re counting on your donation to keep us going strong. Please give today. Every dollar makes a difference—in fact, gets tripled! Thank you so much.
-Amy Goodman

Non-commercial news needs your support.

We rely on contributions from you, our viewers and listeners to do our work. If you visit us daily or weekly or even just once a month, now is a great time to make your monthly contribution.

Please do your part today.

Donate

NY Drops Indoor Mask Mandate; Pfizer Projects Over $50 Billion in Revenue from COVID Treatments

HeadlineFeb 09, 2022

New York has become the latest Democrat-led state to drop some of its COVID restrictions, lifting its indoor mask-or-vaccine mandate for businesses starting today. Governor Kathy Hochul has not yet announced the future of New York’s schools mask mandate, which is set to expire in two weeks.

Pfizer announced a projected $32 billion in revenue this year from its publicly funded COVID-19 vaccine. That’s just part of Pfizer’s overall projected revenue of around $100 billion in 2022, with another $22 billion coming from the sale of its COVID pill Paxlovid. Pfizer has refused to share its technology with other countries in desperate need of vaccines. Oxfam said in response to Pfizer’s financial report, “Thousands of people in Africa are dying every day from COVID because companies like Pfizer have prioritized profits over saving lives. … No corporations should decide who lives and who dies.”

In other vaccine news, Johnson & Johnson has halted production of its coronavirus vaccine. The Dutch plant making the only usable doses of the shot switched over to production of an experimental vaccine unrelated to COVID. The pause, which started at the end of last year, is expected to last a few months. Many African nations, as well as the COVAX distribution program, rely heavily on J&J’s one-dose vaccine.

The original content of this program is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License. Please attribute legal copies of this work to democracynow.org. Some of the work(s) that this program incorporates, however, may be separately licensed. For further information or additional permissions, contact us.

Non-commercial news needs your support

We rely on contributions from our viewers and listeners to do our work.
Please do your part today.
Make a donation
Top